Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer

Campone, Mario; De Laurentiis, Michelino; Jhaveri, Komal; Hu, Xichun; Ladoire, Sylvain; Patsouris, Anne; Zamagni, Claudio; Cui, Jiuwei; Elena Cazzaniga, Marina; Çil, Timuçin; J. Jerzak, Katarzyna; Fuentes, C.S.; Yoshinami, Tetsuhiro; Rodríguez-Lescure, Álvaro; Sezer, Ahmet; Fontana, Andrea; Guarneri, Valentina; Molckovsky, Andrea; Mouret‐Reynier, Marie‐Ange; Demırcı, Umut; Zhang, Yongqiang; Valota, Olga; R. Lu, Dongrui; Martignoni, Marcella; Parameswaran, Janaki; Zhi, Xin; Hamilton, Erika

doi:10.1056/nejmoa2505725

Public

Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer

Published in New England Journal of Medicine • May 31, 2025

Authors:

Mario Campone

Michelino De Laurentiis

Komal Jhaveri

Abstract

BackgroundVepdegestrant is an oral proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader that directly harnesses the ubiquitin–proteasome system. MethodsIn this phase 3, open-label, randomized trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HE...

Subject

Breast cancer

Estrogen receptor

Estrogen

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!